Early trial drug for chronic-phase CML after prior treatments
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 study tests ELVN-001 in people with chronic-phase chronic myeloid leukemia (CML) who have had limited benefit or side effects from other CML medicines. It may help shrink leukemia activity safely and find the best dosing for people who still need treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have CML that is in the chronic phase (not advanced/blast phase).
- Your leukemia test (BCR-ABL1) is positive, even if you have the T315I mutation.
- You have tried at least one prior second-generation CML pill (a “targeted kinase inhibitor”) and it either didn’t work or you couldn’t tolerate it (or you cannot take available active options).
- Your general functioning is good enough for daily activities (ECOG 0 to 2).
- Your blood counts and organ tests (kidney, liver, and bone marrow) are within acceptable ranges.
- Your heart rhythm on an ECG must not show a QTc longer than 470 ms (a measurement related to electrical timing).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new targeted pill called TERN-701 for people with chronic myeloid leukemia (CML) that has not responded well to or caused side effects from other targeted therapies. The goal is to see if it is safe and effective.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
This trial tests an experimental drug called TGRX-678 for people with a specific, more advanced stage of chronic myeloid leukemia (CML) called 'accelerated phase.' It’s for patients whose cancer has stopped responding to or who couldn't tolerate earlier targeted therapies (tyrosine kinase inhibitors).
This trial tests a new combination of three drugs (a third-generation TKI, azacitidine, and a Bcl-2 inhibitor) for people with chronic myeloid leukemia that has progressed to a more advanced phase (myeloid blast phase). The goal is to see if this combination is safe and effective.
This trial tests the drug olverembatinib alone for people with newly diagnosed chronic phase CML who have not had much prior treatment. It aims to see how well the drug works and what side effects it may cause.
This Phase 1 study tests HQP1351 for people with CML or Ph+ ALL that has not responded well to standard targeted pills (TKIs), or those who could not tolerate them. It’s designed to see whether the treatment can work and how safe it is for this difficult-to-treat group.
Hear when a new Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.